Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs

• Main Authors: Deanna M. Mudie (Author), Aaron M. Stewart (Author), Jesus A. Rosales (Author), Nishant Biswas (Author), Molly S. Adam (Author), Adam Smith (Author), Christopher D. Craig (Author), Michael M. Morgen (Author), David T. Vodak (Author)
• Format: Book
• Published: MDPI AG, 2021-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Calquence^® (crystalline acalabrutinib), a commercially marketed tyrosine kinase inhibitor (TKI), exhibits significantly reduced oral exposure when taken with acid-reducing agents (ARAs) due to the low solubility of the weakly basic drug at elevated gastric pH. These drug-drug...